AVPR2 and Renal cyst: The V2R antagonist tolvaptan, by inhibiting the binding of vasopressin to the receptor, promotes aquaresis and lowers cAMP synthesis, slowing progression of renal cysts also in humans as shown in randomized placebo-controlled clinical trials56–59.